The BOOST trial - led by researchers at the University of Plymouth and experts across the UK - will assess whether the Β-hydroxy β-methylbutyrate (HMB) supplement can benefit some of the 60,000 people ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...

Akero Therapeutics’ impressive performance in both stock price and clinical trials has made it a stock to watch in 2025. With a promising treatment on the horizon and significant gains to show for it, ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

A new study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric surgery significantly ...

Key Takeaways Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.The drug, known as EFX, helped reverse ...

Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...

SNUBBING Dry January and continuing to drink like it’s Christmas may seem like a great way to get through the dreary first ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

A Cleveland Clinic study reveals that bariatric surgery significantly reduces the risk of serious liver complications in ...